Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2

Hu,Ruyi; Liu,Wenming; Qiu,Xingfeng; Lin,Zhenghe; Xie,Yan; Hong,Xingya; Paerhati,Reyila; Qi,Zhongquan; Zhuang,Guohong; Liu,Zhongchen

doi:10.3892/ol.2016.4133

Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2

Authors:
- Ruyi Hu
- Wenming Liu
- Xingfeng Qiu
- Zhenghe Lin
- Yan Xie
- Xingya Hong
- Reyila Paerhati
- Zhongquan Qi
- Guohong Zhuang
- Zhongchen Liu
View Affiliations

Affiliations: Organ Transplantation Institute, Anti‑Cancer Research Center, Medical College, Xiamen University, Xiamen, Fujian 361100, P.R. China, Division of Gastroenterology Surgery, Zhongshan Hospital, Gastroenterology Institute of Xiamen University, Gastroenterology Center of Xiamen, Xiamen, Fujian 361000, P.R. China, Department of Ultrasound, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361100, P.R. China
Published online on: January 20, 2016 https://doi.org/10.3892/ol.2016.4133
Pages: 1835-1840

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor (TNF)-α-induced protein 8 (TIPE) is a recently identified protein that is considered to be associated with various malignancies, including esophageal, breast and pancreatic cancer; however, the importance of TIPE in gastric cancer (GC) remains unknown. Decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor superfamily that is expressed in digestive system neoplasms. The expression of DcR3 is regulated by the mitogen‑activated protein kinase (MAPK)/MAPK kinase/extracellular signal‑regulated kinase (ERK) signaling pathway. Reverse transcription‑polymerase chain reaction was performed to detect the expression of TIPE, ERK and DcR3 in the pathological and tumor‑adjacent normal gastric tissues of 30 patients that demonstrated stage III gastric adenocarcinoma. The expression and distribution of the TIPE protein was examined using immunohistochemistry, and the clinical significance and expression levels of DcR3 and ERK1/2 were evaluated. The expression of TIPE, ERK1/2 and DcR3 in the tumor tissues of GC was significantly increased compared with paracarcinoma tissues (P<0.05). In addition, TIPE expression positively correlated with DcR3 and ERK1 levels (r=0.538 and r=0.462, respectively; P<0.05). There was no statistical difference between tumor tissues from patients with varying age, gender, differentiation or lymph node metastasis (P>0.05). TIPE may be vital in the progression of GC. TIPE may be associated with the expression of DcR3 and ERK1/2, which may be involved in the cell apoptosis of GC. The present study elucidates the potential function of TIPE as a novel marker and therapeutic target for GC.

View Figures

View References

1	Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
3	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
4	Patel S, Wang FH, Whiteside TL and Kasid U: Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: Implications in metastasis and/or radiation response. Oral Oncol. 33:197–203. 1997. View Article : Google Scholar : PubMed/NCBI
5	Kumar D, Gokhale P, Broustas C, Chakravarty D, Ahmad I and Kasid U: Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene. 23:612–616. 2004. View Article : Google Scholar : PubMed/NCBI
6	You Z, Ouyang H, Lopatin D, Polver PJ and Wang CY: Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem. 276:26398–26404. 2001. View Article : Google Scholar : PubMed/NCBI
7	Laliberté B, Wilson AM, Nafisi H, Mao H, Zhou YY, Daigle M and Albert PR: TNFAIP8: A new effector for Galpha(i) coupling to reduce cell death and induce cell transformation. J Cell Physiol. 225:865–874. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhang C, Kallakury BV, Ross JS, Mewani RR, Sheehan CE, Sakabe I, Luta G, Kumar D, Yadavalli S, Starr J, et al: The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer. 133:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
9	Dong QZ, Zhao Y, Liu Y, Wang Y, Zhang PX, Jiang GY, Dong XJ, Cui QZ and Wang EH: Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci. 101:1562–1569. 2010. View Article : Google Scholar : PubMed/NCBI
10	Duan D, Zhu YQ, Guan LL and Wang J: Upregulation of SCC-S2 in immune cells and tumor tissues of papillary thyroid carcinoma. Tumour Biol. 35:4331–4337. 2014. View Article : Google Scholar : PubMed/NCBI
11	Laliberté B, Wilson AM, Nafisi H, Mao H, Zhou YY, Daigle M and Albert PR: TNFAIP8: A new effector for Galpha(i) coupling to reduce cell death and induce cell transformation. J Cell Physiol. 225:865–874. 2010. View Article : Google Scholar : PubMed/NCBI
12	Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH and Teh BT: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wu Y, Guo E, Yu J, Xie Q and Chen J: High DcR3 expression predicts stage pN2 in GC. Hepatogastroenterology. 54:2172–2176. 2007.PubMed/NCBI
14	Yang D, Fan X, Yin P, Wen Q, Yan F, Yuan S, Liu B, Zhuang G and Liu Z: Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer. BMC Immunol. 13:282012. View Article : Google Scholar : PubMed/NCBI
15	Kleihues P and Sobin LH: World Health Organization classification of tumours. Cancer. 88:28872000. View Article : Google Scholar : PubMed/NCBI
16	Sobin LH and Wittekind C: International Union Against Cancer (UICC). TNM Classification of Malignant Tumours (6th). (New Jersey). Wiley Blackwell, Hoboken. 2002.
17	Freundt EC, Bidere N and Lenardo MJ: A different TIPE of immune homeostasis. Cell. 133:401–402. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X and Chen YH: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 133:415–426. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kumar D, Whiteside TL and Kasid U: Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin- 1beta-converting enzyme-inhibitory protein. J Biol Chem. 275:2973–2978. 2000. View Article : Google Scholar : PubMed/NCBI
20	Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
21	Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A and Weller M: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61:2759–2765. 2001.PubMed/NCBI
22	Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:699–703. 1998. View Article : Google Scholar : PubMed/NCBI
23	Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP and Caskey CT: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA. 97:1230–1235. 2000. View Article : Google Scholar : PubMed/NCBI
24	Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi H, Koizumi M, Toyoda E and Ito D: Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer. 106:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
25	Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem. 274:13733–13736. 1999. View Article : Google Scholar : PubMed/NCBI
26	Song H, Lee AY, Jung H, Choi JH, Roh K, Ha S, Kim KD, Bae KB, Kang MS, Park S, et al: A8, an anti-uPA agonistic antibody, promotes metastasis of cancer cells via ERK pathway. Monoclon Antib Immunodiagn Immunother. 33:312–318. 2014. View Article : Google Scholar : PubMed/NCBI
27	Jerjees DAI, Alabdullah M, Alkaabi M, Abduljabbar R, Muftah A, Nolan C, Green AR, Ellis IO and Rakha EA: ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast Cancer Res Treat. 147:25–37. 2014. View Article : Google Scholar : PubMed/NCBI